Moderna Stock-Based Compensation — Historical Data
Moderna (MRNA) stock-based compensation was $483M in FY2025 (+13% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$483M
+13%
2024
$429M
+41%
2023
$305M
+35%
2022
$226M
+59%
2021
$142M
+53%
2020
$93M
+15%
2019
$81M
+12%
2018
$73M
+81%
2017
$40M
+2%
2016
$39M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q2 2026
$120M
Q1 2026
$104M
Q4 2025
$113M
Q3 2025
$125M
Q2 2025
$130M
Q1 2025
$115M
Q4 2024
$104M
Q3 2024
$112M
Q2 2024
$112M
Q1 2024
$101M
Q4 2023
$79M
Q3 2023
$77M
Source: MRNA on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.